Biosimilars | Emerging Biosimilars | Oncology: Zarxio Launch Tracking (US) Wave 3 is the third and final installment in a series of syndicated reports designed to track physician perception and uptake of Sandoz’s Zarxio (filgrastim-sndz), a biosimilar of Amgen’s Neupogen and the first biosimilar to launch in the United States. Medical oncologists and hematology-oncologists in the United States were surveyed to assess their awareness and perception of Zarxio, uptake of the biosimilar over time, Zarxio's effect on other G-CSFs, and promotional activity related to Zarxio and its competitors. Formulary coverage and restrictions associated with Zarxio and other G-CSFs were also evaluated.

Table of contents

  • Biosimilars - Emerging Biosimilars - Oncology: Zarxio Launch Tracking (US) Wave 3
    • Key Findings
      • Zarxio Awareness and Promotional Activity for G-CSFs
      • Who Are Zarxio Prescribers and Nonprescribers?
      • Differences Between Zarxio Prescriber and Nonprescriber Profiles
      • Who Is the Zarxio Patient?
      • Zarxio-Treated Patients by Indication
      • Trends in Zarxio Uptake
      • Patient Share of Filgrastim Products by Practice Type
      • Quarterly U.S. Sales of Short-Acting G-CSFs
    • Benchmarking Zarxio Launch Success versus Other New Products
      • Benchmarking Zarxio Launch Success Versus Other New Products
    • Formulary Analysis
      • Introduction
        • U.S. Payer-Reported Coverage of G-CSFs
      • Formulary Coverage of G-CSFs
        • G-CSF Coverage Among Commercial Plans
        • G-CSF Coverage Among Medicare Plans
      • Zarxio Formulary Coverage Compared with Neupogen
        • Zarxio Commercial and Medicare Coverage Compared with Neupogen
      • Granix Formulary Coverage Compared with Neupogen
        • Granix Commercial and Medicare Coverage Compared with Neupogen
      • Changes in Formulary Status of G-CSFs
        • Changes in Formulary Status October 2015-September 2016: Commercial
        • Changes in Formulary Status October 2015-September 2016: Medicare
    • Zarxio Awareness and Perceptions
      • Unaided Awareness of Biologics for Treatment/Prevention of Chemotherapy-Induced Neutropenia
        • Biologics Recalled for Chemotherapy-Induced Neutropenia
      • Level of Familiarity with Biosimilars and Zarxio
        • Level of Familiarity with Biosimilars
        • Level of Familiarity with Zarxio
      • Physician Perception of Indications in Which Zarxio Was Studied
        • Indications in Which Physicians Believe Zarxio Was Clinically Studied Prior to Approval
      • Physician Perception of Zarxio’s Approved Indications
        • Indications Physicians Believe Zarxio Is Approved to Treat
      • Physician Perception of Indications Zarxio Should Be Approved to Treat
        • Indications Physicians Believe Zarxio Should Be Approved to Treat
    • Zarxio Trial and Use
      • Patients Prescribed Zarxio
        • Number of Cancer Patients Receiving Myelosuppressive Chemotherapy Who Have Received Zarxio
        • Number of Hematology-Oncology Patients Who Have Received Zarxio
        • Healthcare Coverage for Zarxio-Treated Patients
        • Healthcare Coverage for Neutropenia Patients
        • Proportion of Zarxio-Treated Patients Who Were G-CSF-Naive or Switched from Another G-CSF
        • Current G-CSF Patient Share
        • Current Patient Share of Long- and Short-Acting G-CSFs by Prescriber Status
      • Prescribers' Experience of Zarxio
        • Proportion of Oncologists Who Have Prescribed Zarxio to at Least One Patient
        • Reasons for Choosing to Prescribe Zarxio
        • Prescribers' Perception of Zarxio’s Similarity to Neupogen
        • Reported Differences Between Zarxio and Neupogen
        • Overall Level of Satisfaction with Zarxio
        • Perceived Discount of Zarxio Compared with Neupogen Net Cost
        • WAC per Unit and Discount Relative to Neupogen for Filgrastim Products
        • WACs per mcg and Medicare Part B Payment Limits for Filgrastim Products
      • Reasons for Not Prescribing Zarxio
        • Oncologists' Reasons for Not Prescribing Zarxio
    • External Factors Affecting Use
      • Factors That Could Increase Use of Zarxio
        • Factors That Would Encourage Use or Increase Use of Zarxio
      • Sources of Pressure or Recommendations to Use Zarxio
        • Sources of Pressure for the Use of Zarxio Instead of Other G-CSF Brands
      • Predicted Uptake of Zarxio by Healthcare Coverage
        • Predicted Variability in Zarxio Uptake Depending on Patients’ Healthcare Coverage
        • Reasons for Rapid Uptake of Zarxio
      • Rate of Acceptance of Zarxio by Patients
        • Percentage of Patients Who Accepted Zarxio When Proposed
        • Percentage of Oncologists Who Have Never Proposed Use of Zarxio
      • Opinions on Nonproprietary Names for Biosimilars
        • Oncologists' Opinions on Nonproprietary Names for Biosimilars
    • Promotional Activity
      • Most Recent Contact with Sales Representatives
        • Most Recent Contact with Medical Sales Representatives for Zarxio and Competitors
      • Topics of Discussion with Medical Representatives
        • Topics Discussed with Medical Representatives
    • Future Use of Biosimilars
      • Zarxio's Influence on Willingness to Use Other Biosimilars
        • Likelihood of Prescribing Other Biosimilars as a Result of Zarxio Use: Medical Oncologists
        • Likelihood of Prescribing Other Biosimilars as a Result of Zarxio Use: Hematology-Oncologists
      • Likelihood of Prescribing Different Filgrastim Biosimilars
        • Likelihood of Prescribing Other Filgrastim Biosimilars
      • Future Patient Share Expectations for G-CSFs
        • Future G-CSF Patient Share If Pegfilgrastim Biosimilars Are Unavailable: Medical Oncologists
        • Future G-CSF Patient Share If Pegfilgrastim Biosimilars Are Unavailable: Hematology-Oncologists
        • Future G-CSF Patient Share If Pegfilgrastim Biosimilars Are Available
        • Future Patient Share of Long- and Short-Acting G-CSFs by Prescriber Status
        • Future Patient Share of Long- and Short-Acting G-CSF Biosimilars by Prescriber Status
    • Appendix
      • Background on the U.S. G-CSF Market
        • Overview
        • Product Information: Short-Acting G-CSFs
        • Approved Indications for Short-Acting G-CSFs in the United States
        • Product Information: Long-Acting G-CSFs
        • Approved Indications for Long-Acting G-CSFs in the United States
        • G-CSF Market News
        • Assumptions Supporting U.S. Launch Date Estimates for Future G-CSF Biosimilars
        • Clinical Trial Information for Zarxio
      • Methodology and Objectives
        • Objectives
        • Methodology
        • Number of Study Participants
        • Significance Testing in This Study
      • Respondent Demographics
        • Respondents' Practice Location
        • Distribution of Respondents by Region
        • Years in Clinical Practice
        • Practice Type
        • Number of Patients Receiving Myelosuppressive Chemotherapy Managed Per Month: Medical Oncologists
        • Number of Adult Cancer Patients Under Management per Month: Hematology-Oncologists
        • Number of Pediatric Cancer Patients Under Management per Month: Hematology-Oncologists
        • Drugs Prescribed by Medical Oncologists
        • Drugs Prescribed by Hematology-Oncologists
      • Table of Abbreviations

Author(s): Marta Delgado

Marta Delgado, Ph.D. is a Business Insight Analyst in the Biosimilars Research team, responsible for the analysis of the biosimilars market across four main therapeutic areas – oncology, endocrinology, immunology and nephrology. Marta holds a Ph.D. in Molecular Neuroscience from University College of London (UCL) and a B.Sc. in Biomedicine from University Pompeu Fabra (UPF), Barcelona. Prior to joining the Biosimilars Research team, Marta worked as a Research Analyst at SKIM, specialising in advanced quantitative studies assessing the potential market opportunities to support life sciences companies in their business decision making.


Related Reports

Biosimilars - Market Events And Forecast - Oncology

In 2019, sales of branded monoclonal antibody biologics in oncology exceeded $18 billion across the major markets (United States, EU5, and Jap...

View Details

Biomarkers In Oncology - Access & Reimbursement - Detailed, Expanded Analysis (US) Biomarkers In Oncology

Biomarkers have become an integral component of the treatment landscape for an increasing number of oncology indications. Patients’ biomarker status often directs prescription choice in malig...

View Details

Biosimilars - Geographic Focus: China - Biosimilars | China In-Depth | Oncology And Immunology | China

The approval of Shanghai Henlius Biotech's HLX01—a biosimilar of Roche's Rituxan (rituximab)—in February 2019 marked the beginning of the biosimilars era in China. Since then, b...

View Details

Biosimilars - Emerging Biosimilars - Special Topics: Oncology Biosimilars In The United States - Wave 2

Biosimilars referencing Roche/Genentech’s portfolio of blockbuster oncology monoclonal antibodies—Avastin, Herceptin, and Rituxan—launched in the United States throughout the seco...

View Details